CompletedNCT02146547
Long-Acting Antipsychotic Medicines for Schizophrenia
About this title
Read the official source — NCT02146547Medication studyAges 18+Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Innsbruck and 48 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: February 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 536
- Sponsor
- UMC Utrecht
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United Kingdom, Belgium, Austria, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT02146547
- Official title
Show the full official title
European Long-acting Antipsychotics in Schizophrenia Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Innsbruck, Austria · Vienna, Austria · Antwerp, Belgium
43 more locations
- Sofia, Bulgaria
- Hradec Králové, Czechia
- Brno, Czechia
- Prague, Czechia
- Glostrup Municipality, Denmark
- Düsseldorf, Germany
- München, Germany
- Halle, Germany
- Athens, Greece
- Balassagyarmat, Hungary
- Budapest, Hungary
- Bat Yam, Israel
- Be’er Ya‘aqov, Israel
- Jerusalem, Israel
- Pardesiyya, Israel
- Petah Tikva, Israel
- Tel HaShomer, Israel
- Naples, Italy
- Turin, Italy
- L’Aquila, Italy
- Utrecht, Netherlands
- Bergen, Norway
- Stavanger, Norway
- Trondheim, Norway
- Warsaw, Poland
- Lublin, Poland
- Arad, Romania
- Bucharest, Romania
- Buzău, Romania
- Craiova, Romania
- Targu Mureş, Romania
- Barcelona, Spain
- Santander, Spain
- Oviedo, Spain
- Madrid, Spain
- London, United Kingdom
- Manchester, United Kingdom
- Kent, United Kingdom
- Middlesbrough, United Kingdom
- Newcastle, United Kingdom
- Oxford, United Kingdom
- Surrey, United Kingdom
- Czechia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is UMC Utrecht.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole, Aripiprazole depot, Paliperidone and Paliperidone palmitate.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia